A Phase 3 interventional study of BP lowering drugs (nicardipine, labetalol, urapidil) and BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil) in Acute Ischemic Stroke, sponsored by Yonsei University. Recruiting at 1 site in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Yonsei University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Ischemic Stroke by Yonsei University — 4 open to participants now, 5 under way, 2 of them phase 3. Ischemic Stroke · Yonsei University.
Among the 11 studies in Ischemic Stroke by Yonsei University, this one is the only one that started in 2024, is one of 3 in phase 3, and was the 9th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →4 of the 11 studies in Ischemic Stroke by Yonsei University are open now, in 1 country. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
Ages 20+
Yonsei University · Sites in Korea, Republic of
Ages 20+
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 176 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 118 across the 6 interventional studies, 400 across the 5 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yonsei University is the lead sponsor of 1,421 studies on the registry; 241 are open to participants now.
1 of the studies in Ischemic Stroke by Yonsei University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06770426Phase 3Yonsei UniversityCompARing Between CO2 Phenylephrine and Phenylephrine Only Treatment in Patients With proGrEssing Cerebral infarctioN | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Ischemic Stroke by Yonsei University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Though intravenous thrombolysis has been shown to improve symptoms in acute ischemic stroke patients, the recanalization rate remains low (22.6%) and only around 30% of patients benefit from the treatment. Recently, endovascular thrombectomy using stent retrievers or catheters has proven to be more effective, with a success rate of nearly 80%. However, only 50% of patients experience clinical improvement, highlighting the need for new treatment strategies to enhance outcomes. Current guidelines recommend maintaining systolic blood pressure (BP) below 180 mmHg after thrombectomy, but there is a lack of evidence regarding optimal blood pressure management post-reperfusion.
Four randomized clinical trials, including the OPTIMAL-BP trial, have examined blood pressure control following thrombectomy. Meta-analyses showed that intensive BP lowering did not reduce symptomatic hemorrhage and was associated with worse functional outcomes at 3 months. Specifically, lowering BP too aggressively after successful reperfusion could worsen outcomes by reducing perfusion to the ischemic penumbra. Therefore, this study will investigate whether a more targeted blood pressure elevation strategy could improve patient prognosis compared to standard BP control in patients with sustained systolic blood pressure (SBP) \<150 mmHg on successive measurements obtained less than 10 minutes apart within 3 hours after reperfusion.
This is a prospective, randomized, open-label trial with blinded endpoint assessment (PROBE) design, aimed at comparing intensive and standard BP control strategies in acute ischemic stroke patients. Participants will be randomized 1:1 into either an intensive BP control group (targeting a 20% systolic BP increase, capped at less than 160 mmHg) or a standard BP control group (systolic BP at or below 180 mmHg).
\<Inclusion Criteria>
\<Exclusion Criteria>
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BP lowering drugs (nicardipine, labetalol, urapidil)
Drug: BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil)
After successful reperfusion, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.
After successful reperfusion, appropriate BP raising (20% increase in SBP, maximum of 160 from baseline SBP) are administered.
Functinal independence
Proportion of patients with a functional independence (defined as mRS ≤ 2) at 3 months, assessed using the modified Rankin Scale (mRS).
Time frame: 3 months
Symptomatic Intracranial Hemorrhage (sICH)
Symptomatic Intracranial Hemorrhage (sICH) after Endovascular Treatment Intracranial hemorrhage or hemorrhagic transformation identified on MRI (GRE or SWI) or CT within 24 ± 12 hours or due to clinical worsening. (Symptomatic intracranial hemorrhage is defined according to the European Cooperative Acute Stroke Study III \[ECASS III\] criteria)
Time frame: 36 hours
Stroke related death
Stroke related death within 3 months
Time frame: 3 months
Shift analysis of mRS score distribution.
Distributional analysis of the modified Rankin Scale (mRS) scores to assess overall functional outcome shift between treatment groups.
Time frame: 3 months
NIHSS score at 24 hours after endovascular treatment.
Difference in National Institutes of Health Stroke Scale (NIHSS) scores between at 24 hours post-EVT.
Time frame: 24 hours
Major Neurological Improvement at 24 hours, defined as either an NIHSS score of 0-1 or an improvement of 8 or more points.
Proportion of patients achieving substantial neurological recovery within 24 hours after EVT.
Time frame: 3 months
Sustained vessel recanalization on CTA/MRA at 24 hours
Evaluation of angiographic reperfusion status (modified Thrombolysis in Cerebral Infarction \[mTICI\] grade ≥2b)
Time frame: Discharge and 1 month
Proportion of functional independence at 1 month.
Percentage of patients achieving mRS 0-2 at 1 month.
Time frame: 3 months
Differences in Euro-Q5 instrument.
Differences in scores measured by Euro-Q5 scale.
Time frame: 36 hours to 1 week
Incidence of malignant cerebral edema.
Frequency of radiologically or clinically confirmed malignant cerebral edema after EVT.
Time frame: 36 hours
Infarction volumes
Proportion of functional independence according to infarction volumes in DWI
Time frame: 36 hours
Using intravenous BP lowering drug
Proportion of functional independence according to intrvenous BP lowering drug
Time frame: 3 months
Medication induced BP drop
Proportion of functional independence according to medication inuced BP drop
Time frame: 3 months
Collateral circulation measured by Tan scale (good collateral is defined as Tan scale 2-3) in baseline CTA.
Proportion of functional independence according to the degree of collateral flow
Time frame: 3 months
Variability in blood pressure (e.g., standard deviation, coefficient of variation, VIM, successive variation, and threshold).
Evaluation of outcome associations with multiple BP variability indices
Time frame: 3 months
Outcome comparison by baseline ischemic core burden measured with ASPECTS.
Proportion of functional independence according to the ASPECTS (Alberta Stroke Program Early CT Score) on CT or MRI.
Time frame: 3 months
Evaluation of differential outcomes in patients who received IV tPA before EVT.
Proportion of functional independence according to prior tPA administration.
Time frame: 3 months
Comparison of outcomes according to presence or severity of intracranial atherosclerotic stenosis.
Proportion of functional independence according to intracranial arterial stenosis.
Time frame: 3 months
Assessment of outcome differences by number of thrombectomy passes.
Proportion of functional independence according to multiple attempts at endovascular recanalization.
Time frame: 3 months
Evaluation of outcomes relative to attainment and timing of post-EVT BP target.
Proportion of functional independence according to achieving the target blood pressure and the time to target on outcomes.
Time frame: 3 months
Outcome comparison by initial angiographic reperfusion grade before BP intervention.
Proportion of functional independence according to baseline mTICI scores.
Time frame: 3 months
Assessment of outcome differences between patients with and without early neurological worsening.
Proportion of functional independence according to neurological deterioration (NIHSS worsening by ≥4 points).
Time frame: 3 months
Evaluation of outcomes stratified by occlusion site (e.g., ICA, M1, M2).
Proportion of functional independence according to the occluded vessel involved.
Time frame: 3 months
Biochemical markers including D-dimer, CRP, or glucose
Proportion of functional independence according to laboratory findings including D-dimer, CRP, or glucose.
Time frame: 3 months
Evaluation of vascular stiffness as a determinant of post-EVT outcomes.
Proportion of functional independence according to estimated pulse wave velocity (ePWV).
Time frame: 3 months
Small artery disease - white matter hyperintensity
Proportion of functional independence according to degree of white matter hyperintensity
Time frame: 3 months
Small artery disease - microbleeds
Proportion of functional independence according to number of microbleeds
Time frame: 3 months
Small artery disease - old lacunar infarction
Proportion of functional independence according to number of old lacunar infarctions
Time frame: 3 months
Optimal target BP according to AI predicting for functional independence in 10 mmHg increments
Model-based identification of the optimal SBP target range predicted by AI for favorable outcomes.
Time frame: 3 months
Occurrence of adverse event or serious adverse event
Incidence and type of adverse events
Time frame: 3 months
Treatment failure, defined as failure to achieve target blood pressure on two consecutive measurements within 24 hours after endovascular therapy.
Rate of unsuccessful BP target attainment during the acute post-procedure period.
Time frame: 24 hours
Differences in BP variability depending on the antihypertensive agent use (labetalol or nicardipine).
Comparison of short-term BP stability between BP medication used for post-EVT management.
Time frame: 24 hours
Differences in causes of death.
Comparison of mortality causes
Time frame: 3 months
Diffrences in fuctional outcomes at 1 year.
Difference in 1-year functional outcomes according to mRS and EQ-5D-5L.
Time frame: 1 year
Euro-Q5-5L analogue scale.
Differnec in scores measured by Euro-Q5 scale.
Time frame: 1 year
Plan to share: Yes — After study competition, the participating researcher can submitt the proposal. Publication committee will evaluate the proposal and approve it. After approval, patients data will be shared with researcher.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: The data will be available until the study was published.
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Dec 2029, 62 months after the start.
Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 62 months is above that.
Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phenylephrine